Key result
Dapagliflozin consistently cuts worsening HF or CV death in HF with LVEF >40% across regions.
Why the study?
Patients with HF with mildly reduced or preserved ejection fraction in Asia may have different clinical characteristics and outcomes compared with patients from other parts of the world, prompting evaluation of dapagliflozin safety and efficacy in patients in Asia versus outside Asia.
Does enrollment in Asia versus outside Asia modify the efficacy and safety of dapagliflozin in reducing worsening heart failure or cardiovascular death in patients with heart failure and LVEF >40%?
RCT (n=6,263)
Double-blind
Randomized to receive dapagliflozin 10 mg daily or a matching placebo
Yes
Does enrollment in Asia versus outside Asia modify the efficacy and safety of dapagliflozin in reducing worsening heart failure or cardiovascular death in patients with heart failure and LVEF >40%?
In the DELIVER trial, dapagliflozin consistently reduced the risk of cardiovascular death or worsening heart failure and improved symptoms in patients with HFmrEF/HFpEF enrolled in Asia just as effectively and safely as in patients outside Asia, despite notable regional differences in baseline comorbidities and mortality rates.
Answers are grounded in this paper and cite their sources.
Supports dapagliflozin for HF with LVEF >40% in Asia; confirms consistent benefit irrespective of region.
Patients with heart failure (HF) with mildly reduced or preserved ejection fraction in Asia may have different clinical characteristics and outcomes compared with patients from other parts of the world. The purpose of this study was to investigate the clinical characteristics, safety, and efficacy of dapagliflozin in patients in Asia vs outside Asia in the DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure) trial. In the DELIVER trial, patients with HF and left ventricular ejection fraction >40% were enrolled across 353 sites in 20 countries. The effects of dapagliflozin vs placebo on primary (composite of worsening HF or cardiovascular death) and secondary outcomes were compared in patients from Asia vs outside Asia. Among 6,263 participants, 1,226 (19.6%) were enrolled in Asia. Participants from Asia were less likely to have diabetes, hypertension, history of myocardial infarction, or obesity. After adjusting for clinically relevant characteristics, those in Asia had similar risks of primary composite outcome compared with those from outside Asia (HR: 0.97; 95% CI: 0.82-1.15). Those in Asia had a lower risk of all-cause mortality compared with those enrolled outside Asia (HR: 0.54; 95% CI: 0.44-0.66). Enrollment from Asia did not modify the effect of dapagliflozin on the primary outcome (Pinteraction = 0.54). Serious adverse events and rates of drug discontinuation were also balanced in both treatment arms, irrespective of enrollment in Asia vs outside Asia. In the global DELIVER trial, dapagliflozin reduced the risk of CV death or worsening HF events and was well tolerated among participants enrolled in both Asia and other geographic regions.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) conducted an RCT in Heart failure with mildly reduced or preserved ejection fraction (LVEF >40%) (n=6,263). Dapagliflozin (and geographic enrollment in Asia vs outside Asia) vs. Matching placebo (and enrollment outside Asia) was evaluated on Composite of worsening heart failure (HF hospitalization or urgent HF visit) or cardiovascular death (Asia vs outside Asia) (HR 0.97, 95% CI 0.82-1.15, p=0.73 (Pinteraction = 0.54 for dapagliflozin effect)). Dapagliflozin consistently reduced worsening HF or CV death in patients with HF and LVEF >40% regardless of enrollment in Asia vs outside Asia, with similar adjusted primary outcome risk between regions.
Synapse has enriched 10 related papers. Consider them for comparative context: